← Back to Home

Intercepting Disease-Causing Proteins Before They Take Shape: Pfizer Teams Up with Enodia to Develop Sec61 Small-Molecule Drugs

A collaboration with a potential total value exceeding $500 million is betting on an intracellular protein transport checkpoint. Whether this approach can selectively eliminate disease-causing proteins while preserving normal physiological functions will be key to its progress toward clinical development.

By SURL BioNews

To exert their effects, disease-causing proteins often must first undergo processing inside cells, then reach the cell surface or be secreted. Intercepting them at the start of this journey could allow treatment to intervene earlier. Pfizer and Enodia Therapeutics announced a research collaboration and licensing agreement on October 13 to jointly develop small-molecule drugs targeting Sec61, exploring the possibility of directing specific disease-causing proteins toward degradation during synthesis.

Sec61 is a protein translocation complex located in the endoplasmic reticulum membrane. Many secreted and membrane proteins must pass through it to enter the endoplasmic reticulum before undergoing further processing and transport. Enodia’s strategy is to selectively modulate this checkpoint, preventing disease-causing proteins from reaching their destinations through the normal pathway and allowing cells to clear them. However, normal proteins also depend on the same transport system; achieving sufficient selectivity is the central question this approach must address.

Under the collaboration, Enodia will be responsible for screening, optimizing, and developing Sec61 inhibitor candidates. After the collaboration period ends, Pfizer will take over clinical development, manufacturing, regulatory affairs, and commercialization. Enodia is entitled to an upfront payment and may receive subsequent research, development, and sales milestone payments, as well as tiered royalties based on net sales. The potential total value of more than $500 million cited by the company does not mean it has already received that funding; the upfront payment amount and the conditions for the various payments have not been disclosed.

Enodia’s accumulated compound and biological data provide the foundation for drug discovery. According to the company and reporting by *Genetic Engineering & Biotechnology News*, its platform encompasses multiple families of Sec61 inhibitors, combining proteomics, cryo-electron microscopy data, and a database of specially engineered cell lines, with machine learning used to assist small-molecule design. These tools are intended to help identify molecules with selectivity for different proteins. This announcement did not provide model prediction accuracy, quantitative validation results for drug candidates, or human efficacy data.

The two companies have also not specified which diseases the collaboration will target. BioSpace reported that it had asked the companies for further details. It is therefore not yet possible to determine which patients might benefit or confirm when the first candidate will enter human trials. Preserving essential physiological functions is a goal of the collaboration that still requires demonstration through subsequent experiments and clinical studies.

This collaboration builds on Pfizer and Enodia’s existing investment relationship: Pfizer Ventures co-led the €20.7 million seed financing round Enodia announced in January 2026. In March of the same year, Enodia acquired Kezar Life Sciences’ Sec61 drug discovery and development assets. The company said these assets help deepen its understanding of the mechanisms underlying selectivity, adding to the research and development foundation for the current collaboration.

By moving from investment to joint development, Pfizer is providing resources for further development of an approach that remains under exploration. Beyond the size of the deal, however, the drugs’ prospects will ultimately depend on whether a viable therapeutic window can be achieved between inhibiting disease-causing proteins and maintaining normal protein transport. Disclosure of specific target proteins, indications, and safety data will gradually clarify the medical value of this collaboration.

References

  1. Enodia Therapeutics
  2. BioSpace
  3. Genetic Engineering & Biotechnology News